These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 29687361)

  • 1. Tildrakizumab-asmn: What's in a Name?
    Yang EJ; Beck KM; Liao W
    Am J Clin Dermatol; 2018 Jun; 19(3):291-292. PubMed ID: 29687361
    [No Abstract]   [Full Text] [Related]  

  • 2. Maintaining 'standards' for biosimilar monoclonal antibodies.
    Prior S; Metcalfe C; Hufton SE; Wadhwa M; Schneider CK; Burns C
    Nat Biotechnol; 2021 Mar; 39(3):276-280. PubMed ID: 33664522
    [No Abstract]   [Full Text] [Related]  

  • 3. Stakeholders discuss biosimilar naming, substitution.
    Traynor K
    Am J Health Syst Pharm; 2014 Mar; 71(6):446-7. PubMed ID: 24589534
    [No Abstract]   [Full Text] [Related]  

  • 4. FDA issues guidelines for biosimilar drugs.
    Cancer Discov; 2012 Mar; 2(3):196. PubMed ID: 22585973
    [No Abstract]   [Full Text] [Related]  

  • 5. Biosimilars take center stage.
    Adams KT
    Manag Care; 2014 Apr; 23(4):44-6. PubMed ID: 24864533
    [No Abstract]   [Full Text] [Related]  

  • 6. Tildrakizumab: First Global Approval.
    Markham A
    Drugs; 2018 Jun; 78(8):845-849. PubMed ID: 29752706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biosimilars: what's in a name?
    Silverman E
    BMJ; 2014 Jan; 348():g272. PubMed ID: 24443479
    [No Abstract]   [Full Text] [Related]  

  • 8. Monoclonal antibody: the corner stone of modern biotherapeutics.
    Xia ZN; Cai XT; Cao P
    Yao Xue Xue Bao; 2012 Oct; 47(10):1275-80. PubMed ID: 23289138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors influencing the economics of biosimilars in the US.
    Mehr SR; Brook RA
    J Med Econ; 2017 Dec; 20(12):1268-1271. PubMed ID: 28796564
    [No Abstract]   [Full Text] [Related]  

  • 10. Biosimilar and interchangable biologic medications.
    Simonson W
    Geriatr Nurs; 2016; 37(5):393-394. PubMed ID: 27637457
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical trial development for biosimilars.
    Alten R; Cronstein BN
    Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S2-8. PubMed ID: 26058550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In this issue... PPP: what's new in the treatment, pathogenesis and terminology?
    Michaëlsson G
    Acta Derm Venereol; 2008; 88(2):99. PubMed ID: 18311432
    [No Abstract]   [Full Text] [Related]  

  • 13. Biosimilars in psoriasis: the future or not?
    Kellen R; Goldenberg G
    Cutis; 2017 Feb; 99(2):116-120. PubMed ID: 28319617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antibody therapeutics: an American view of an amazing present and future].
    Reichert JM
    Med Sci (Paris); 2019 Dec; 35(12):924-925. PubMed ID: 31903895
    [No Abstract]   [Full Text] [Related]  

  • 15. Current Japanese Regulatory Systems for Generics and Biosimilars.
    Kuribayashi R; Sawanobori K
    J Pharm Sci; 2018 Mar; 107(3):785-787. PubMed ID: 29113922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biopharmaceuticals and biosimilars in psoriasis: what the dermatologist needs to know.
    Strober BE; Armour K; Romiti R; Smith C; Tebbey PW; Menter A; Leonardi C
    J Am Acad Dermatol; 2012 Feb; 66(2):317-22. PubMed ID: 22243723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Biosimilars - Potential, risks and open questions].
    Dtsch Med Wochenschr; 2014 Jan; 139(1-2):12-3. PubMed ID: 24551883
    [No Abstract]   [Full Text] [Related]  

  • 18. Some thoughts on the QR method for analytical similarity evaluation.
    Son S; Oh M; Choo M; Chow SC; Lee SJ
    J Biopharm Stat; 2020 May; 30(3):521-536. PubMed ID: 32089068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Similar names for similar biologics.
    Casadevall N; Felix T; Strober BE; Warnock DG
    BioDrugs; 2014 Oct; 28(5):439-44. PubMed ID: 25001080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Considerations in the early development of biosimilar products.
    Li EC; Abbas R; Jacobs IA; Yin D
    Drug Discov Today; 2015 May; 20 Suppl 2():1-9. PubMed ID: 25572407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.